1Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal woman with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple outcomes of Raloxifene Evalu ation (MORE) Investigato
2Lippman ME, Kreuger KA, Eckert S, et al. Indicators of lifetime estrogenexposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study patientsl[ J ]. J Clin Oncol, 2001, 19:3111
3Uesugi T, Toda T, Tsuji K, et al. Comparative study on reduction of bone loss and lipid metabolism abnormality in ovariectomized rats by soy flavones daidzin genistin and glytin[J]. BiolPharm Bull, 2001, 24:368-372
4The Writing group for the women's Health Initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal woman: principleresults from the Woman's Health Initiative randomized controlled trial[ J ].JAMA, 2002, 288:321-333
5Kanis JA. Treatment of osteoporiosis in elderly women[J]. Am J Med, 1995,98 (Suppl 2A) :60-66
6Kiel DP, Felsom P T, Anderson J J, et al. Hip fractureand the use of estrogen in postmenopausal women: the Framingham study[J]. N Engl Med, 1987,317:1169-1174
7Potter SM, Baum JM, Teng H, et al. Soy protein and isoflavone: their ef fects on blood lipids and bone, density in postmenopausal women[J]. Am J Clin Nutr , 1998,68(Suppl) :S1375-1379
8Alekel DC, Germain AS, Peterson CT, et al. Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women[ J ]. Am J Clin Nutr, 2000, 72:844-852
9Amin S, La Valley MP, Simms RN, et al. The role of vitamin D in corticosteroid-induced osteoporosis: a meta- analytic approach[J]. Arthritis Rheum, 1999, 42:1740-1751
10Hock JM, Gera I. Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone [J]. J Bone Miner Res, 1992, 7:65-72
